1. Home
  2. CCCC vs GLU Comparison

CCCC vs GLU Comparison

Compare CCCC & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCCC
  • GLU
  • Stock Information
  • Founded
  • CCCC 2015
  • GLU 2004
  • Country
  • CCCC United States
  • GLU United States
  • Employees
  • CCCC N/A
  • GLU N/A
  • Industry
  • CCCC Biotechnology: Pharmaceutical Preparations
  • GLU Finance/Investors Services
  • Sector
  • CCCC Health Care
  • GLU Finance
  • Exchange
  • CCCC Nasdaq
  • GLU Nasdaq
  • Market Cap
  • CCCC 104.4M
  • GLU 99.4M
  • IPO Year
  • CCCC 2020
  • GLU N/A
  • Fundamental
  • Price
  • CCCC $2.26
  • GLU $17.76
  • Analyst Decision
  • CCCC Buy
  • GLU
  • Analyst Count
  • CCCC 3
  • GLU 0
  • Target Price
  • CCCC $12.00
  • GLU N/A
  • AVG Volume (30 Days)
  • CCCC 2.0M
  • GLU 12.4K
  • Earning Date
  • CCCC 08-04-2025
  • GLU 01-01-0001
  • Dividend Yield
  • CCCC N/A
  • GLU 8.60%
  • EPS Growth
  • CCCC N/A
  • GLU N/A
  • EPS
  • CCCC N/A
  • GLU 0.62
  • Revenue
  • CCCC $39,783,000.00
  • GLU N/A
  • Revenue This Year
  • CCCC N/A
  • GLU N/A
  • Revenue Next Year
  • CCCC N/A
  • GLU N/A
  • P/E Ratio
  • CCCC N/A
  • GLU $22.50
  • Revenue Growth
  • CCCC 98.56
  • GLU N/A
  • 52 Week Low
  • CCCC $1.09
  • GLU $11.61
  • 52 Week High
  • CCCC $7.36
  • GLU $15.40
  • Technical
  • Relative Strength Index (RSI)
  • CCCC 60.73
  • GLU 64.74
  • Support Level
  • CCCC $2.15
  • GLU $17.26
  • Resistance Level
  • CCCC $2.53
  • GLU $17.79
  • Average True Range (ATR)
  • CCCC 0.28
  • GLU 0.18
  • MACD
  • CCCC 0.02
  • GLU -0.01
  • Stochastic Oscillator
  • CCCC 62.13
  • GLU 90.00

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

Share on Social Networks: